Videos

Tucatinib | Breast Cancer | Abstract 1005

Tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)

Tucatinib | Breast Cancer | Abstract 1043/128

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)

Enfortumab Vedotin | Urothelial Carcinoma | Abstract 441

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death

Tisotumab vedotin | Research | Abstract 617

Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): outcomes by hormone receptor status

Tucatinib | Breast Cancer | Abstract 117

Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with active brain metastases

Tucatinib | Breast Cancer | Poster PD13-04

SGN-CD30C | Preclinical Research | Abstract 2889/6

SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies

Tucatinib | Preclinical Research | Abstract 1962/29

Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors

Tucatinib | Preclinical Research | Abstract 4222/26

Tucatinib, a selective small molecule HER2 inhibitor, is active in HER2 mutant driven tumors

Tucatinib | Clinical Research | Abstract 3015/3

Tucatinib inhibits creatinine and metformin renal tubule secretion but has no effect on renal function (GFR)

Tucatinib | Clinical Research | Abstract 3016/4

Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers

Enfortumab vedotin | Urothelial Carcinoma| Abstract 393

Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma

Enfortumab vedotin| Urothelial Carcinoma| Abstract 394

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors

Tucatinib | Breast Cancer | Abstract 2073

Impact of Tucatinib on Progression Free Survival in Patients with HER2+ Metastatic Breast Cancer and Brain Metastases

Tucatinib | Breast Cancer | Abstract 2067

Impact of Tucatinib on Health-Related Quality of Life (HRQoL) in Patients with HER2+ Metastatic Breast Cancer (MBC) with and without Brain Metastases (BM)

Tisotumab vedotin | Cervical Cancer | Abstract 3435

Tisotumab vedotin (TV) in previously treated recurrent or metastatic cervical cancer (r/mCC): results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study

Enfortumab vedotin | Urothelial Cancer | Abstract 2223

EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors

Brentuximab vedotin | Classical Hodgkin Lymphoma | Abstract 2973

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Stud

Brentuximab Vedotin in Combination with Nivolumab Proposed Mechanism of Action

Learn about the proposed mechanism of action of brentuximab vedotin in combination with nivolumab

Tucatinib Proposed Mechanism of Action

Learn about the proposed mechanism of action of tucatinib

Enfortumab Vedotin Proposed Mechanism of Action

Learn about the proposed mechanism of action of enfortumab vedotin

Tisotumab Vedotin Proposed Mechanism of Action

Learn about the proposed mechanism of action of tisotumab vedotin

SEA Technology

Learn about sugar-engineered antibody technology

Vedotin ADC Technology

Learn about vedotin antibody–drug conjugate technology

Enfortumab Vedotin Proposed Mechanism of Action in Combination with PD-1 Inhibitor Therapy

Learn about the proposed mechanism of action of enfortumab vedotin in combination with PD-1 inhibitory therapy